Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $85.00 at Chardan Capital

Monopar Therapeutics (NASDAQ:MNPR) had its price objective upped by Chardan Capital from $60.00 to $85.00 in a research report report published on Thursday, MarketBeat Ratings reports. Chardan Capital currently has a buy rating on the stock.

A number of other research firms have also recently weighed in on MNPR. Lake Street Capital assumed coverage on Monopar Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $106.00 price target on the stock. HC Wainwright started coverage on Monopar Therapeutics in a research note on Tuesday, August 26th. They issued a “buy” rating and a $70.00 price target for the company. BTIG Research upped their price objective on shares of Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday. Raymond James Financial initiated coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $80.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $74.00 price target on shares of Monopar Therapeutics in a report on Wednesday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $82.33.

Monopar Therapeutics Trading Up 6.0%

NASDAQ MNPR opened at $77.44 on Thursday. The firm has a market capitalization of $477.80 million, a P/E ratio of -23.26 and a beta of 1.20. The firm’s fifty day moving average price is $43.86 and its two-hundred day moving average price is $39.04. Monopar Therapeutics has a 1 year low of $4.50 and a 1 year high of $79.80.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12. On average, research analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Activity

In related news, Director Kim R. Tsuchimoto sold 8,904 shares of Monopar Therapeutics stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $356,160.00. Following the sale, the director directly owned 11,486 shares of the company’s stock, valued at approximately $459,440. The trade was a 43.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Chandler Robinson sold 16,800 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the transaction, the chief executive officer owned 73,472 shares of the company’s stock, valued at approximately $2,938,880. This represents a 18.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,504 shares of company stock worth $1,700,160. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Affinity Asset Advisors LLC bought a new stake in Monopar Therapeutics during the 1st quarter worth $2,257,000. Geode Capital Management LLC boosted its stake in shares of Monopar Therapeutics by 99.7% during the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after purchasing an additional 48,379 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Monopar Therapeutics during the first quarter worth about $673,000. Jane Street Group LLC bought a new stake in shares of Monopar Therapeutics during the first quarter worth about $377,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $328,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.